Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Johns Hopkins Genomics, |
RCV001257135 | SCV001433659 | uncertain significance | Autoimmune interstitial lung disease-arthritis syndrome | 2019-12-03 | criteria provided, single submitter | clinical testing | COPA c.2809G>A has not been reported in ClinVar nor the literature, to our knowledge. This variant (rs552778606) is rare (<0.1%) in a large population dataset (gnomAD: 2/251438 total alleles; 0.0008%; no homozygotes). Of three bioinformatics tools queried, two predict that the substitution would be damaging, while one predicts that it would be tolerated. The glutamic acid residue at this position is highly evolutionarily conserved across all species assessed. Due to insufficient evidence that this variant is deleterious, we consider the clinical significance of c.2809G>A to be uncertain at this time. |
Labcorp Genetics |
RCV001257135 | SCV002260234 | likely benign | Autoimmune interstitial lung disease-arthritis syndrome | 2022-07-12 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002570617 | SCV003589078 | uncertain significance | Inborn genetic diseases | 2021-11-29 | criteria provided, single submitter | clinical testing | The c.2836G>A (p.E946K) alteration is located in exon 27 (coding exon 27) of the COPA gene. This alteration results from a G to A substitution at nucleotide position 2836, causing the glutamic acid (E) at amino acid position 946 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |